Iovance Biotherapeutics is at the forefront of cancer treatment innovation, primarily through its Tumor Infiltrating Lymphocyte (TIL) therapy. This approach utilizes the body's own immune cells, specifically TILs, which are naturally occurring immune cells that can recognize and attack cancer cells. In Iovance's process, TILs are collected from a patient's tumor, expanded and reinvigorated in a controlled manufacturing environment, and then reintroduced into the patient as a personalized treatment. This therapy aims to enhance the immune response against various advanced solid tumors, including melanoma and non-small cell lung cancer (NSCLC). The company is also exploring the combination of TIL therapy with immune checkpoint inhibitors to improve treatment efficacy.

In addition to TIL therapy, Iovance is developing a Peripheral Blood Lymphocyte (PBL) therapy platform for blood cancers. This platform focuses on utilizing polyclonal T cells derived from a patient's blood sample, which are then amplified and reinvigorated before being infused back into the patient. The PBL therapy is designed to target and attack diverse blood cancer cells, offering a personalized treatment option. Iovance is committed to advancing these T-cell-based immunotherapy technologies through ongoing clinical trials and research initiatives, including genetically modified TIL therapies that aim to enhance the potency and effectiveness of cancer treatments.

United States

Iovance Biotherapeutics (NASDAQ: IOVA) aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer.

We are adding to our talented team as we execute our commercial launch, advance our research and development efforts, and build our internal manufacturing capabilities. Iovance is headquartered in the San Francisco Bay Area. Our Iovance Cell Therapy Center (iCTC), a state-of-the-art manufacturing facility, is located in Philadelphia. We also have a research site in Tampa, Florida. 

Any information expressed by Iovance is subject to the risk factors and information on forward-looking statements contained in its filings with the Securities and Exchange Commission and available here: https://ir.iovance.com/sec-filings 


Cancer

Hematologic Diseases

Lung Diseases

Skin Diseases

Urogenital Diseases

Iovance Biotherapeutics

Melanoma

Iovance TIL technology is designed to address the manifold obstacles that attenuate the natural anti-tumor immune response.
<ol class="font_7">
 <li>TIL are extracted from the patient and expanded to billions in number by stimulating them ex vivo (in tissue culture) with IL-2.</li>
 <li>The amplification process eliminates the immune-suppressive environment created by the tumor which is so effective at neutralizing the natural anti-tumor immune response.</li>
 <li>This same culture environment optimizes the replication and activation of aggressive anti-tumor TIL. Once sufficient numbers of cells with the appropriate anti-tumor potential have been cultured, they are then re-administered back into the patient where they have been shown to mediate impressive anti-tumor responses with strong durability after a one-time administration.</li>
</ol>

AMTAGVI™ (Lifileucel)

Non-small cell lung carcinoma

Iovance TIL (LN-145)

Iovance TIL technology is designed to address the manifold obstacles that attenuate the natural anti-tumor immune response.
<ol class="font_8">
 <li>TIL are extracted from the patient and expanded to billions in number by stimulating them ex vivo (in tissue culture) with IL-2.</li>
 <li>The amplification process eliminates the immune-suppressive environment created by the tumor which is so effective at neutralizing the natural anti-tumor immune response.</li>
 <li>This same culture environment optimizes the replication and activation of aggressive anti-tumor TIL. Once sufficient numbers of cells with the appropriate anti-tumor potential have been cultured, they are then re-administered back into the patient where they have been shown to mediate impressive anti-tumor responses with strong durability after a one-time administration</li>
</ol>

Iovance TIL (LN-145) or lifileucel +/- pembrolizumab

Cervical cancer

Lifileucel  

Endometrial cancer

IOV-4001

San Carlos, California, United States, Philadelphia, Pennsylvania, Tampa, Florida

Iovance Biotherapeutics

Company Details